180 Life Sciences Corp. has announced new compensation terms for its executive officers, effective June 17, 2025. The company's Board of Directors, with input from the Compensation Committee, has approved the granting of stock options and restricted shares under the 2025 Option Incentive Plan. Chief Executive Officer Blair Jordan has been awarded options to purchase 410,000 shares and 167,576 shares of restricted common stock. Chief Accounting Officer Eric R. Van Lent has received options for 25,000 shares and 8,174 restricted common shares. These options, with an exercise price of $0.9290 per share, are set to vest semi-annually over a year, contingent upon continued service with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063799), on July 14, 2025, and is solely responsible for the information contained therein.